Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avonex: Phase III data; marketed to treat relapsing-remitting MS

An independent data monitoring committee recommended early termination of BGEN's 383-patient North American Phase III

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE